To further validate the concept of specific MTH1 inhibitor for cancer treatment, Helleday et al.37–40 then described a new best-in-class MTH1 inhibitor (TH1579, Karonudib) (WO2015187088A1), which has been approved for phase I clinical testing in cancer patients with advanced solid malignancies (NCT03036228). Here, NUDT1 is linked to cancer.